BioCorRx

BioCorRx R&D per Employee

The R&D Spending per Employee of BioCorRx (BICX) as of Sep 27, 2026 is 296,580.00 USD. In the previous year, R&D Spending per Employee was 178,220.00 USD — a change of 66.41% (higher).

R&D per Employee

296,580.00USD

YoY

66.41%

Last updated:

R&D Spending per Employee of BioCorRx is 2026 296,580.00 USD. R&D Spending per Employee of BioCorRx was 2025 178,220.00 USD. It decreases by 66.41% higher compared to the previous year.

The BioCorRx R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2017
90,000.00 USD
Jan 1, 2018
30,000.00 USD
Jan 1, 2019
226,000.00 USD
Jan 1, 2020
854,000.00 USD
Jan 1, 2021
322,000.00 USD
Jan 1, 2022
292,000.00 USD
Jan 1, 2023
178,220.00 USD
Jan 1, 2024
296,580.00 USD
The BioCorRx R&D per Employee history
YEARR&D per EmployeeYoY
296,580.00USD+66.41%
178,220.00USD-38.97%
292,000.00USD-9.32%
322,000.00USD-62.30%
854,000.00USD+277.88%
226,000.00USD+653.33%
30,000.00USD-66.67%
90,000.00USD—
Access this data via the Eulerpool API

BioCorRx Stock analysis

What does BioCorRx do? The company BioCorRx Inc is a US-American company that was founded in 2008 and is headquartered in Anaheim, California. BioCorRx specializes in the development and marketing of innovative treatment methods for alcohol and drug dependency. The history of BioCorRx began with the introduction of its flagship product, the BioCorRx Recovery Program, which is based on a novel medical technology called Naltrexone/Buprenorphine Implant. Unlike traditional methods of treating alcohol and drug addiction, which typically rely on medication and psychotherapeutic support, the BioCorRx Recovery Program is an implantable, long-term treatment system that continuously delivers the active ingredient Naltrexone or Buprenorphine into the patient's body. The idea behind this is that the active ingredients prevent withdrawal symptoms and thereby reduce the risk of relapse. In recent years, BioCorRx has expanded its product portfolio and expanded its business activities to new segments in order to further drive the company's growth. This includes, for example, the field of telemedicine services, which allow BioCorRx to offer its treatment technology and medical services through online communication. Telemedicine services such as virtual patient consultation or online group therapy programs are particularly in demand in times of COVID-19. Another focus of BioCorRx is the management of medical personnel. Studies have shown that good patient care and counseling heavily influence the success of treatment. BioCorRx has now also developed its own platform that eases and improves the management, training, and monitoring of medical staff. BioCorRx also utilizes the concept of franchise systems to market its products and services. The franchise system offers medical professionals and organizations working in the field of addiction treatment the opportunity to open their own BioCorRx clinic and offer the company's products and services in their local market. Each clinic is advised and supported by BioCorRx and must adhere to certain standards and quality criteria. In the future, BioCorRx plans to further diversify its product offering and develop new technologies to improve treatment options for alcohol and drug dependents. An example of such a technology is medication based on Ibogaine. BioCorRx has already started initial research in this direction and is actively working on pre-clinical studies. Overall, BioCorRx is a company that primarily focuses on innovative technologies for the treatment of addiction. The company has experienced substantial growth in recent years by expanding its product range and customer base, and focusing on the areas of telemedicine, personnel management, and franchise systems. With its forward-thinking technologies and strong emphasis on quality and patient satisfaction, BioCorRx is expected to continue playing an important role in addiction treatment in the years to come. BioCorRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCorRx stock

R&D Spending per Employee of BioCorRx is 296,580.00 USD in 2026.

R&D Spending per Employee of BioCorRx changed from 178,220.00 USD to 296,580.00 USD, representing a 66.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee BioCorRx since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's BioCorRx historically and in real time.

Access this data via the Eulerpool API

Workforce — BioCorRx

All Key Metrics — BioCorRx